Protagonist Stock 120%, Fund Outlook and Exit Signals
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Identify practical ways to prepare your budget for surprises through proactive adjustments and an emergency fund, strengthening your financial footing.
19,028 articlesA hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
A fintech just reported a blowout quarter, yet the stock still looks cheap to patient investors. This analysis breaks...
A major hedge fund recently disclosed a new stake in BORR, signaling a strategic bet in the offshore drilling sector....
When a fintech stock investor trims a large stake in a rising Brazilian payments firm, traders and everyday investors...
A biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
Momentum can flip quickly in growth stocks, but today some names look cheap for the upside potential. This guide high...
Investors are watching whether NVIDIA back business China could unlock a new revenue stream. This analysis covers sce...
Howard Lindzon’s work with StockTwits and Social Leverage reshapes how we think about investing in communities. This ...
A once-popular retirement tactic tied to Dave Ramsey’s stealth social approach faces renewed scrutiny in 2026 as infl...
As investors eye pagseguro (pags) 2026 earnings, this guide breaks down what to watch, how growth could unfold, and p...
A large stake exit sent shockwaves through a payments stock, pulling it down by about half from its highs. This artic...
Gossamer Bio's 2026 earnings outlook centers on cash runway, pipeline progress, and strategic partnerships. This arti...